Soleno Therapeutics Surges on $2.5 Billion Neurocrine Biosciences Buyout Talks

Soleno Therapeutics stock is rallying sharply following a report that the company is in talks to be acquired by Neurocrine Biosciences for approximately $2.5 billion. The potential deal, which would represent a significant premium, has sent Soleno shares soaring as investors react to the prospect of a major consolidation in the rare disease therapeutics space.

The reported discussions center on Neurocrine, a well-established neuroscience-focused biopharmaceutical company, acquiring Soleno, a clinical-stage biotech developing treatments for rare genetic disorders. The $2.5 billion valuation underscores the high stakes and intense competition for promising late-stage assets, particularly in neurology. Soleno's lead candidate, diazoxide choline controlled-release (DCCR) for Prader-Willi syndrome, is a key driver of its valuation and likely a primary target for Neurocrine's strategic expansion.

If finalized, this acquisition would mark one of the larger biotech buyouts of the year, signaling continued aggressive M&A activity by larger pharmaceutical firms seeking to bolster their pipelines. The deal talks place immediate pressure on both companies' boards and could prompt scrutiny from regulators. For the broader biotech sector, a successful transaction at this scale would reinforce the premium placed on innovative, late-stage rare disease programs and may intensify speculation around other potential takeover targets in the neurology and endocrine spaces.